Product Description
Bristol-Myers Squibb is developing bms-986278, an Oral LPA1 Antagonist for Lung fibrosis
Mechanisms of Action: LPA1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: Breakthrough Therapy - Pulmonary Fibrosis|Progressive Pulmonary Fibrosis *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, Japan, Korea, Mexico, Netherlands, Peru, Poland, Portugal, Puerto Rico, Spain, Sweden, Switzerland, Taiwan, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis
Phase 2: Pulmonary Fibrosis
Phase 1: Healthy Volunteers|Kidney Failure, Chronic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IM027-1015 | P3 |
Recruiting |
Progressive Pulmonary Fibrosis |
2027-12-27 |
|
| jRCT2021230026 | P3 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2027-12-03 |
|
| jRCT2021230037 | P3 |
Recruiting |
Progressive Pulmonary Fibrosis |
2027-09-02 |
|
| IM027-068 | P3 |
Recruiting |
Idiopathic Pulmonary Fibrosis |
2026-10-26 |